Understanding Senolytics and Their Role in Aging Research

Senolytic drugs represent one of the most promising frontiers in aging biology, targeting senescent cells—dysfunctional cells that stop dividing but remain metabolically active, secreting inflammatory factors known as the senescence-associated secretory phenotype (SASP). These cells accumulate with age, contributing to chronic inflammation, tissue dysfunction, and diseases like Alzheimer's, diabetes, and frailty. By selectively eliminating them, senolytics aim to rejuvenate tissues and extend healthspan.

Dasatinib and quercetin (D+Q), the first widely studied senolytic combination, pair dasatinib—a tyrosine kinase inhibitor originally approved for chronic myeloid leukemia—with quercetin, a natural flavonoid found in fruits and vegetables. Preclinical studies have shown D+Q clearing senescent cells in various tissues, improving physical function in aged mice, reducing kidney inflammation in diabetic patients, and alleviating frailty symptoms in early human trials. However, most research has focused on peripheral organs, leaving central nervous system (CNS) effects underexplored—until now.

This gap is critical because the brain's unique environment, including the blood-brain barrier, may alter drug behavior. With over 50 million Americans aged 65+ projected by 2030 and neurodegenerative diseases rising, safe brain-targeted senolytics could transform higher education research agendas in neuroscience and gerontology.

The UConn Crocker Lab's Landmark PNAS Publication

Researchers from the Crocker Lab at the University of Connecticut School of Medicine, led by immunologist Stephen Crocker, published "Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum" in the Proceedings of the National Academy of Sciences (PNAS) on March 17, 2026. Co-authors include former lab members Evan Lombardo (now at Dartmouth) and Robert Pijewski (Anna Maria College), alongside Zaenab Dhari and Anirudhya Lahiri.

The study emerged from efforts to test whether D+Q could rejuvenate myelin-producing oligodendrocytes in multiple sclerosis (MS) models. Instead, it revealed unexpected neuropathology in healthy brains. Crocker's team used C57BL/6J mice—young (3-4 months or 6-9 months) and aged (22 months)—administering standard D+Q doses (dasatinib 5 mg/kg + quercetin 50 mg/kg, typically intermittent). They examined the corpus callosum, a white matter tract connecting brain hemispheres essential for cognition and motor control.

"When you administer this cocktail to an animal, young or old, the myelin is damaged, which makes it disappear. Even worse in the young animals," Crocker stated.

Experimental Methods: From Mice to Cell Cultures

The in vivo arm involved treating naive mice (no disease model) with D+Q or vehicle, then assessing myelination via electron microscopy, immunohistochemistry for myelin basic protein (MBP), and luxol fast blue staining. G-ratios (axon diameter/total diameter) quantified demyelination—higher ratios indicate thinner myelin sheaths.

In vitro, primary rat oligodendrocyte progenitor cells (OPCs) were cultured in differentiation media with D+Q. Time-lapse videos captured process retraction without cell death, while bulk RNA sequencing revealed upregulated endoplasmic reticulum (ER) stress genes and unfolded protein response (UPR) pathways via Ingenuity Pathway Analysis.

• Electron microscopy: Reduced myelin thickness, elevated G-ratios in D+Q-treated corpus callosum.
• Immunostaining: Fewer mature oligodendrocytes, more immature forms.
• qPCR/Western blot: Downregulated MBP and myelin oligodendrocyte glycoprotein (MOG).

No neuronal loss or astrogliosis occurred, isolating effects to oligodendroglia.

Key Findings: D+Q Triggers Myelin Loss Without Cell Death

D+Q induced significant demyelination in the corpus callosum of both age groups, but more severely in younger mice—challenging assumptions that senolytics primarily benefit aged tissues. The corpus callosum area diminished, akin to "chemo brain" post-chemotherapy.

Oligodendrocytes didn't die; they regressed, retracting processes and halting myelination. This mirrors dysfunctional cells in MS lesions, where OPCs fail to mature.

Mechanisms Unveiled: Energy Starvation and UPR Activation

Crocker hypothesizes D+Q disrupts oligodendrocyte energy metabolism: "We suspect the drugs are choking off energy the cells need, and the cells respond by reducing complexity, reverting to a younger state, but less functional."

Dasatinib inhibits tyrosine kinases vital for mitochondrial function; quercetin may exacerbate ER stress. RNA-seq confirmed UPR activation—CHOP, ATF4 upregulation—forcing cells into survival mode, prioritizing basics over myelination. This step-by-step process: (1) Drug entry stresses ER, (2) Protein misfolding triggers UPR, (3) Transcriptional shift halts differentiation, (4) Process retraction reduces surface area/energy demand.

Paradoxical Ties to Multiple Sclerosis and Brain Aging

MS affects 1 million Americans, with relapsing-remitting progressing to secondary progressive via failed remyelination. Senescent OPCs accumulate in aged white matter, impairing repair. D+Q-regressed cells phenocopy MS oligodendrocytes, offering a novel model. Ironically, prior studies showed D+Q clearing senescent OPCs in Alzheimer's models, improving cognition—but here, off-target hits healthy cells.

For full details, see the PNAS paper.

Clinical Landscape: Ongoing D+Q Trials Amid New Cautions

D+Q is in Phase I/II trials for idiopathic pulmonary fibrosis (completed 2021, improved function), diabetic kidney disease (reduced inflammation 2026), osteoporosis, and frailty. A 2026 trial combines it with temozolomide for glioblastoma. No CNS-focused trials report brain imaging yet, but prophylactic off-label use in biohackers raises alarms.

Read UConn's coverage here.

Implications for Neuroscience and Aging Research in Academia

This UConn breakthrough underscores the need for CNS-specific senolytic screening. Crocker's lab exemplifies translational neuroscience at public universities, training PhDs like Pijewski for faculty roles. It highlights risks in repurposing cancer drugs for aging, urging multi-omics safety profiling.

• Risks: Broad senolytic action hits healthy glia.
• Benefits: Models MS progression/remyelination failure.
• Solutions: Targeted senolytics (e.g., navitoclax alternatives, CAR-T senolytics).

Stakeholder Perspectives and Future Directions

MedicalXpress notes: Findings "raise caution and MS clues." Crocker's team pursues recovery protocols: "If we can mimic this, we have an amazing opportunity to see if the cells can recover and repair the brain."

Horizons include nanoparticle delivery for brain selectivity, senescent-cell biomarkers for patient stratification, and longitudinal human trials with MRI. For academics, this fuels grants in glia biology, with UConn positioning as a hub.

Actionable Insights for Researchers and Students

Replicate with single agents to pinpoint culprits. Explore UPR inhibitors as adjuncts. Students: Pursue OPC electrophysiology, senolytic pharmacodynamics. This paper redefines senolytic drug risks, balancing hype with rigorous science.

Photo by Shawn Day on Unsplash